Protara Therapeutics Inc Market Cap ($142.42 Million)
Market Cap & Net Worth: Protara Therapeutics Inc (TARA)
Protara Therapeutics Inc market cap. Protara Therapeutics Inc (NASDAQ:TARA) has a market capitalization of $142.42 Million ($142.42 Million) as of November 4, 2026. Listed on the NASDAQ stock exchange, this USA-based company holds position #17650 globally and #4182 in its home market, demonstrating a 2.55% increase in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Protara Therapeutics Inc's stock price $2.41 by its total outstanding shares 59095488 (59.10 Million). Also see TARA cash generation efficiency for how efficiently the company converts equity into cash flow.
Protara Therapeutics Inc Market Cap History (2015–2026)
Protara Therapeutics Inc market cap history from 2015 to 2026. Data shows change from $36.66 Billion to $142.42 Million (-39.55% CAGR). Check TARA share price today for real-time trading data and today's change.
Index Memberships
Protara Therapeutics Inc is a constituent of 2 market indices:
| Index | Total Market Cap | Weight (%) | Rank by Market Cap |
|---|---|---|---|
|
NASDAQ Health Care
IXHC
|
$2.61 Trillion | 0.01% | #480 of 976 |
|
NASDAQ Composite
IXIC
|
$40.20 Trillion | 0.00% | #1713 of 3165 |
Weight: Protara Therapeutics Inc's market cap as a percentage of total index value. Rank: Position among all constituents by market cap.
Protara Therapeutics Inc Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Protara Therapeutics Inc's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance. Explore Protara Therapeutics Inc (TARA) net asset momentum to track how rapidly the company is growing its equity base year over year.
Latest Price to Sales (P/S) Ratio
No P/S ratio data available
Latest Price to Earnings (P/E) Ratio
No P/E ratio data available
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| No financial ratio data available | |||||
Competitor Companies of TARA by Market Capitalization
Companies near Protara Therapeutics Inc in the global market cap rankings as of November 4, 2026. Also see TARA total asset value for a full breakdown of the balance sheet.
Key companies related to Protara Therapeutics Inc by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #180 globally with a market cap of $130.90 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #368 globally with a market cap of $76.14 Billion USD.
- CSL Ltd (AU:CSL): Ranked #414 globally with a market cap of $68.22 Billion USD ( AU$96.41 Billion AUD).
- Moderna Inc (NASDAQ:MRNA): Ranked #494 globally with a market cap of $54.14 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #180 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $130.90 Billion | $530.76 |
| #368 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $76.14 Billion | $973.36 |
| #414 | CSL Ltd | AU:CSL | $68.22 Billion | AU$198.72 |
| #494 | Moderna Inc | NASDAQ:MRNA | $54.14 Billion | $228.44 |
Market Capitalization of Protara Therapeutics Inc (2015–2026)
Market capitalization of Protara Therapeutics Inc from 2015 to today. Between 2015 and today, Protara Therapeutics Inc's market cap moved from $36.66 Billion to $ 142.42 Million, with a yearly change of -39.55%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | $142.42 Million | -54.78% |
| 2025 | $314.98 Million | +0.95% |
| 2024 | $312.02 Million | +181.58% |
| 2023 | $110.81 Million | -30.03% |
| 2022 | $158.38 Million | -60.30% |
| 2021 | $398.89 Million | -72.12% |
| 2020 | $1.43 Billion | +47.62% |
| 2019 | $969.17 Million | -81.94% |
| 2018 | $5.37 Billion | +19.47% |
| 2017 | $4.49 Billion | 0.00% |
| 2016 | $4.49 Billion | -87.75% |
| 2015 | $36.66 Billion | -- |
End of Day Market Cap According to Different Sources
On Nov 4th, 2026 the market cap of Protara Therapeutics Inc was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $142.42 Million USD |
| MoneyControl | $142.42 Million USD |
| MarketWatch | $142.42 Million USD |
| marketcap.company | $142.42 Million USD |
| Reuters | $142.42 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About Protara Therapeutics Inc
Protara Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in advancing transformative therapies for the treatment of cancer and rare diseases. The company's lead program is TARA-002, an investigational cell therapy, which is in Phase II clinical trial for the treatment of non-muscle invasive bladder cancer and lymphatic malformations. It is also developing intravenous cholin… Read more